ResMed (NYSE: RMD) reported Q2 EPS of $1.66, $0.06 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.03 million versus the consensus estimate of $990.85 million.

For earnings history and earnings-related data on ResMed (RMD) click here.